Literature DB >> 17032140

Biovariability of plasma adiponectin.

Brett Shand1, Peter Elder, Russell Scott, Christopher Frampton, Jinny Willis.   

Abstract

BACKGROUND: Adiponectin is a cytokine produced by adipose tissue with insulin sensitising and anti-atherosclerotic effects. Low plasma adiponectin levels are used as a marker of the metabolic syndrome and incipient type 2 diabetes.
METHODS: We carried out a series of studies to determine the short- and long-term variability of plasma adiponectin levels, including diurnal and post-prandial changes. These investigations also included examining the effect of frozen storage on plasma adiponectin levels.
RESULTS: A nested study in 10 overweight subjects with the metabolic syndrome and 10 age- and sex-matched controls showed intra-subject variation in adiponectin levels over a 30-day period of 12.2% and 18.8%, respectively, equivalent to reference change values of 1.7 and 3.6 microg/mL. In non-obese subjects, plasma adiponectin levels varied minimally over a 15-month period (baseline, 8.3+/-2.9 microg/mL vs. +15 months, 8.2+/-3.0 microg/mL, p=0.95) and showed only minor diurnal and post-prandial changes (pre-meal, 8.2+/-3.0 microg/mL vs. 3 h post-prandial, 8.3+/-3.1 microg/mL, p=0.60). The adiponectin assay had an intra-assay variation of 8.8%, with storage at -30 degrees C for 33 months or three cycles of freezing and thawing having no discernible effect on adiponectin levels.
CONCLUSIONS: These results demonstrate that plasma adiponectin levels have relatively low biovariability and that adiponectin can be sampled fasting or non-fasting to provide a reliable marker of insulin resistance and incipient type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17032140     DOI: 10.1515/CCLM.2006.227

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  23 in total

1.  Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer.

Authors:  Debora Macis; Sara Gandini; Aliana Guerrieri-Gonzaga; Harriet Johansson; Paolo Magni; Massimiliano Ruscica; Matteo Lazzeroni; Davide Serrano; Massimiliano Cazzaniga; Serena Mora; Irene Feroce; Maria Pizzamiglio; Maria Teresa Sandri; Marcella Gulisano; Bernardo Bonanni; Andrea Decensi
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

2.  Portal vein and systemic adiponectin concentrations are closely linked with hepatic glucose and lipoprotein kinetics in extremely obese subjects.

Authors:  Faidon Magkos; Elisa Fabbrini; Bruce W Patterson; J Christopher Eagon; Samuel Klein
Journal:  Metabolism       Date:  2011-05-31       Impact factor: 8.694

3.  Ictal adipokines are associated with pain severity and treatment response in episodic migraine.

Authors:  Nu Cindy Chai; Bizu Gelaye; Gretchen E Tietjen; Paul D Dash; Barbara A Gower; Linda W White; Thomas N Ward; Ann I Scher; B Lee Peterlin
Journal:  Neurology       Date:  2015-03-06       Impact factor: 9.910

4.  Association of adiponectin with left ventricular mass in blacks: the Jackson Heart Study.

Authors:  Aurelian Bidulescu; Jiankang Liu; Solomon K Musani; Ervin R Fox; Tandaw E Samdarshi; Daniel F Sarpong; Viola Vaccarino; Peter W Wilson; Donna K Arnett; Rebecca Din-Dzietham; Herman A Taylor; Gary H Gibbons
Journal:  Circ Heart Fail       Date:  2011-08-12       Impact factor: 8.790

5.  Serum adiponectin levels in patients with acute coronary syndromes: Serial changes and relation to infarct size.

Authors:  Hadeel Alkofide; Gordon S Huggins; Robin Ruthazer; Joni R Beshansky; Harry P Selker
Journal:  Diab Vasc Dis Res       Date:  2015-07-20       Impact factor: 3.291

6.  A lower serum level of middle-molecular-weight adiponectin is a risk factor for endometrial cancer.

Authors:  Yukari Ohbuchi; Yasunobu Suzuki; Ikuo Hatakeyama; Yoshifumi Nakao; Atsuya Fujito; Tsuyoshi Iwasaka; Keiichi Isaka
Journal:  Int J Clin Oncol       Date:  2013-08-22       Impact factor: 3.402

7.  The effects of macronutrient intake on total and high-molecular weight adiponectin: results from the OMNI-Heart trial.

Authors:  Edwina H Yeung; Lawrence J Appel; Edgar R Miller; W H Linda Kao
Journal:  Obesity (Silver Spring)       Date:  2009-10-29       Impact factor: 5.002

Review 8.  Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans.

Authors:  Michael M Swarbrick; Peter J Havel
Journal:  Metab Syndr Relat Disord       Date:  2008-06       Impact factor: 1.894

9.  A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin.

Authors:  Margaret P Rayman; Gabrielle Blundell-Pound; Roberto Pastor-Barriuso; Eliseo Guallar; Holger Steinbrenner; Saverio Stranges
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

10.  Gender differences in the association of visceral and subcutaneous adiposity with adiponectin in African Americans: the Jackson Heart Study.

Authors:  Aurelian Bidulescu; Jiankang Liu; DeMarc A Hickson; Kristen G Hairston; Ervin R Fox; Donna K Arnett; Anne E Sumner; Herman A Taylor; Gary H Gibbons
Journal:  BMC Cardiovasc Disord       Date:  2013-02-22       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.